About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

TERMINATEDPhase 1NCT00932126

This Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid Tumors

This is the first study using PF-03758309, an oral compound, in patients with advanced solid tumors. In this study different doses of PF-03758309 will be administered to different groups of patients. ...

Lead sponsor: Pfizer•2 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Pfizer

The study was prematurely terminated on 26Jul2011 due to the undesirable PK characteristics of PF-03758309 and the lack of an observed dose-response relationship. There were no safety concerns that contributed to the study termination.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Advanced/metastatic solid tumor that is resistant to standard therapy or for which no standard therapy is available.
•ECOG (Eastern Cooperative Oncology Group) Performance Status (PS) must be 0 or 1.
•Adequate bone marrow, liver and kidney function.

Exclusion Criteria

•Patients with known brain metastases.
•Previous high dose chemotherapy requiring stem cell rescue.
•Prior irradiation to \>25% of the bone marrow.
•Active bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV).
•Current active treatment in another clinical study.
•Pregnancy or breast feeding.
•Active inflammatory gastrointestinal disease, chronic diarrhea (unless related to underlying malignancy or prior related treatment) or history of abdominal fistula, gastrointestinal perforation, peptic ulcer disease, or intra-abdominal abscess within 6 months prior to study enrollment.

Related studies

RECRUITINGPhase 1/2

A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

NCT07060989 · Advanced Solid Tumors

RECRUITINGPhase 1

A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation

NCT06659341 · Advanced Solid Tumors Harboring KRAS G12C Mutation

RECRUITINGPhase 1

A Study of PHST001 in Advanced Solid Tumors

NCT06840886 · Advanced Solid Tumors, Ovarian Cancer, and more

RECRUITINGPhase 1/2

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

NCT05533697 · Advanced Solid Tumors

RECRUITINGPhase 1/2

Study of CM518D1 in Patients With Advanced Solid Tumors

NCT07019779 · Advanced Solid Tumors

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 28, 2015Terms

Trial snapshot

StatusTERMINATED

PhasePHASE1

Enrollment35

Start dateSep 2009

Last updatedOct 28, 2015

Condition

Advanced Solid Tumors

Locations shown

Pfizer Investigational Site

Santa Monica, California

Pfizer Investigational Site

Aurora, Colorado

Pfizer Investigational Site

East Melbourne, Victoria

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 28, 2015Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions